TCR therapy for MM involves engineering patient T cells to target specific antigens such as NY-ESO-1 [37, 114], MAGE-A3 [115, 116], and BCMA [117], which are either unique to or overexpressed by MM cells. The gene discussed is MAGEA3; the disease is Miyoshi myopathy.